Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.648 ^USD	-0.46%		-1.93%	-3.01%

Apr. 23	Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	MT
Apr. 23	Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	CI

Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

June 22, 2021 at 08:00 am EDT

Caladrius Biosciences, Inc. announced that the U.S. Food and Drug Administration has authorized its investigational new drug application for the study of CLBS201, a CD34+ cell therapy for the treatment of diabetic kidney disease.

Latest news about Lisata Therapeutics, Inc.

Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	Apr. 23	MT
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 23	CI
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	Apr. 17	CI
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Apr. 09	CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 21	MT
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	Mar. 21	MT
Transcript : Lisata Therapeutics, Inc., 2023 Earnings Call, Feb 29, 2024	Feb. 29
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme	Jan. 17	CI
Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma	Dec. 12	CI
Transcript : Lisata Therapeutics, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Lisata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents	Nov. 02	CI
Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1	23-10-24	CI
Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma	23-09-06	CI
Transcript : Lisata Therapeutics, Inc., Q2 2023 Earnings Call, Aug 15, 2023	23-08-15
Lisata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Lisata Therapeutics' LSTA1 Malignant Glioma Treatment Candidate Gets FDA Orphan Drug Label	23-08-08	MT
Lisata Therapeutics Shares Down on LSTA1's Orphan Drug Designation	23-08-08	DJ
Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors	23-07-11	CI
Transcript : Lisata Therapeutics, Inc. - Special Call	23-06-21
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1	23-05-24	CI
Transcript : Lisata Therapeutics, Inc., Q1 2023 Earnings Call, May 09, 2023	23-05-09
Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI

Chart Lisata Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.66 USD

Average target price

14.5 USD

Spread / Average Target

+445.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LISATA THERAPEUTICS, INC.	-3.01%	22.1M
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research